v3.26.1
SEGMENT REPORTING
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
SEGMENT REPORTING

 

10. SEGMENT REPORTING

 

The Company manages its operations as a single operating segment, which includes all activities related to the development and potential commercialization of novel therapies for the treatment of cancer, for the purposes of assessing performance and making operating decisions. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company’s chief operating decision maker (“CODM”). The Company’s CODM is its President and Chief Executive Officer, who reviews and evaluates consolidated net income (loss) for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.

 

In addition to the significant expense categories included within consolidated net income (loss) presented on the Company’s unaudited condensed consolidated statements of operations, see below for disaggregated amounts that comprise research and development expenses for the three and six months ended June 30, 2026 and 2025: 

                    
   Three Months Ended June 30,  Six Months Ended June 30,
   2026  2025  2026  2025
Personnel and consulting expenses  $1,031,747   $858,546   $2,240,958   $1,715,239 
External clinical study expenses   772,019    1,521,617    1,353,208    3,355,988 
Nonclinical and biomarker research   197,323    250,811    735,400    343,212 
Chemistry Manufacturing & Control (“CMC”) related costs   65,736    133,831    302,503    570,685 
Total research and development expenses  $2,066,825   $2,764,805   $4,632,069   $5,985,124 

 

In addition, the Company has a wholly-owned subsidiary, Actuate Therapeutics Limited, which is a dormant entity with no assets, liabilities or operations in any foreign countries.